Arovella Therapeutics (FRA:E4NA) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Arovella Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Arovella Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Arovella Therapeutics's long-term debt to total assets ratio stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Arovella Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Arovella Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics LT-Debt-to-Total-Asset Chart

Arovella Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Arovella Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	-	-	-

Arovella Therapeutics LT-Debt-to-Total-Asset Calculation

Arovella Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )	/	Total Assets (A: Jun. 2023 )
	=	0	/	3.389
	=	0.00

Arovella Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0	/	3.27
	=	0.00

Arovella Therapeutics (FRA:E4NA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Arovella Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Arovella Therapeutics (FRA:E4NA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (FRA:E4NA) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ALA:Australia

Address

62 Lygon Street, Level 3, Carlton, WA, AUS, 3053

Website

https://www.arovella.com

Arovella Therapeutics Ltd is a biotechnology company focused on developing therapies to treat human diseases. Its two focus areas are oncology and conditions that impact the central nervous system. The company's principal activity is the pharmaceutical development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer.

Arovella Therapeutics (FRA:E4NA) Headlines

No Headlines